Literature DB >> 16331162

Stereotactic aspiration and antibiotic treatment combined with hyperbaric oxygen therapy in the management of bacterial brain abscesses.

Murat Kutlay1, Ahmet Colak, Senol Yildiz, Nusret Demircan, Osman Niyazi Akin.   

Abstract

OBJECTIVE: Despite advances in surgical techniques in the management of the brain abscess, long-term antibiotics are as crucial to cure as the initial surgical procedure itself. This study was designed to evaluate the effect of adjuvant hyperbaric oxygen (HBO) therapy on the duration of antibiotic treatment.
METHODS: Between 1999 and 2004, 13 patients with bacterial brain abscesses treated with stereotactic aspiration combined with HBO and systemic antibiotic therapy. Patients younger than 18 years of age were excluded from this study. Postoperatively, all patients were given a 4-week course of intravenous antibiotics. Additionally, patients received hyperbaric oxygen (HBO, 100% O2 at 2.5 ATA for 60 min) twice daily for five consecutive days, and an additional treatment (100% O2 at 2.5 ATA for 60 min daily) was given for 25 days.
RESULTS: There were eight male and five female patients. Their ages ranged between 18 and 71 years, with a mean of 43.9 years. The average duration of follow-up was 9.5 months (range, 8-13 mo). This treatment modality allowed infection control and healing for all 13 patients with 0% recurrence rate. HBO treatment was tolerated well, and there were no adverse effects of pressurization. At the end of the follow-up period, 12 patients had a good outcome: nine are without sequelae, and three have a mild hemiparesis but are capable of self-care. One patient has a moderate hemiparesis.
CONCLUSION: Although the number of patients is small, this series represents the largest reported group of brain abscess patients treated with stereotactic aspiration combined with antibiotic and HBO therapy. Our preliminary results indicate that the length of time on antibiotics can be shortened with the use of HBO as an adjunctive treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16331162

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

Review 1.  The structure-function relationship of Pseudomonas aeruginosa in infections and its influence on the microenvironment.

Authors:  Mads Lichtenberg; Tim Holm Jakobsen; Michael Kühl; Mette Kolpen; Peter Østrup Jensen; Thomas Bjarnsholt
Journal:  FEMS Microbiol Rev       Date:  2022-09-02       Impact factor: 15.177

2.  Biodegradable drug-eluting poly[lactic-co-glycol acid] nanofibers for the sustainable delivery of vancomycin to brain tissue: in vitro and in vivo studies.

Authors:  Yuan-Yun Tseng; Yu-Chun Kao; Jun-Yi Liao; Wei-An Chen; Shih-Jung Liu
Journal:  ACS Chem Neurosci       Date:  2013-07-12       Impact factor: 4.418

3.  Drastic therapy for listerial brain abscess involving combined hyperbaric oxygen therapy and antimicrobial agents.

Authors:  Keiichi Nakahara; Satoshi Yamashita; Katsumasa Ideo; Seigo Shindo; Tomohiro Suga; Akihiko Ueda; Shoji Honda; Tomoo Hirahara; Masaki Watanabe; Taro Yamashita; Yasushi Maeda; Yasuhiro Yonemochi; Tomohiro Takita; Yukio Ando
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

4.  CONSORT: May stereotactic intracavity administration of antibiotics shorten the course of systemic antibiotic therapy for brain abscesses?

Authors:  Xin Yu; Rui Liu; Yaming Wang; Hulin Zhao; Jinhui Chen; Jianning Zhang; Chenhao Hu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

5.  Pediatric brain abscess - etiology, management challenges and outcome in Lagos Nigeria.

Authors:  Okezie Obasi Kanu; Omotayo Ojo; Christopher Esezobor; Olufemi Bankole; John Olatosi; Ezekiel Ogunleye; Chinyere Asoegwu; Morgan Eghosa; Bamidele Adebayo; Rita Oladele; Clement Nwawolo
Journal:  Surg Neurol Int       Date:  2021-12-08

6.  Treating Intracranial Abscesses in Rats with Stereotactic Injection of Biodegradable Vancomycin-Embedded Microparticles.

Authors:  Yuan-Yun Tseng; Ching-Wei Kao; Kuo-Sheng Liu; Ya-Ling Tang; Yen-Wei Liu; Shih-Jung Liu
Journal:  Pharmaceutics       Date:  2020-01-22       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.